the remaining RCT, checklist recommended a 'null' application of subgroup analysis for PFS because of inconsistency of results. Conclusion and relevance No differences in OS or PFS according to baseline hepatic function should be considered for daratumumab based combinations in patients with untreated MM. Patients with normal hepatic function and HI could benefit from treatment. Application of subgroup analysis should be considered with caution. Conflict of interest Corporate sponsored research or other substantive relationships MDG-S: membership of an advisory board (consultation fees) and lecture for Janssen Pharmaceutica (reimbursement for attending symposia).

No abstract

Aggressive Fibromatosis (AF) is a rare, benign neoplasm originating from musculoaponeurotic stromal structures characterized by aggressive growth and infiltration of local tissues. To date, there are only six previously reported cases of AF involving the larynx. Our case involves a 70-year-old female with a 5-year history of hoarseness and an enlarging neck mass consistent with aggressive recurrent fibromatosis. MRI showed a large, solid mass arising from the left anterior cervical space displacing the trachea and upper airway to the right. A year after the initial radical resection, the patient presented with recurrence. A second radical excision was performed not including a laryngectomy. Radiation therapy was consulted for possible local treatment to prevent subsequent recurrence of tumor. Literature has reported up to 40-70% recurrence rates of AF within 18 months. There is minimal literature to guide treatment. Surgery seems to be the treatment of choice for head and neck AF, but management of recurrence is controversial.